{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:38:12Z","timestamp":1764733092622,"version":"3.40.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.transproceed.2024.05.034","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T20:15:14Z","timestamp":1722111314000},"page":"1446-1453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cisplatin as a Viable and Secure Alternative to Carmustine in BEAM-Based Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma"],"prefix":"10.1016","volume":"56","author":[{"given":"B.L.","family":"Acosta-Maldonado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Padilla-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-3374","authenticated-orcid":false,"given":"O.E.","family":"Fernandez-Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rivera-Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.M.","family":"Valero-Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Calderon-Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2024.05.034_bib0001","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Eng J Med"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0002","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the american society for transplantation and cellular therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0003","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0004","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/HS9.0000000000000295","article-title":"The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma in the era of CAR-T cell therapy","volume":"3","author":"Lekakis","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0005","doi-asserted-by":"crossref","first-page":"888","DOI":"10.21037\/tcr-22-595","article-title":"Efficacy and safety of autologous hematopoietic stem cell transplantation in the treatment of malignant lymphoma after chemotherapy: a systematic review and meta-analysis","volume":"11","author":"Yu","year":"2022","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.1054314","article-title":"The role of transplantation in Hodgkin lymphoma","volume":"12","author":"Maranzano","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0007","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0008","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/bmt.2016.340","article-title":"Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review","volume":"52","author":"Damaj","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0009","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1182\/blood-2019-127402","article-title":"Outpatient BEAM using daily etoposide and cytarabine with autologous hematopoietic stem cell transplantation for lymphoma is feasible and decreases inpatient length of stay","volume":"134","author":"Cazeau","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0010","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.bbmt.2017.12.074","article-title":"Pharmacoeconomic impact and transplant outcome associated to carmustine (BCNU) substitution with bendamustine (Be) in the conditioning regimen prior to autologous stem cell transplantation for lymphoma treatment","volume":"24","author":"Boisjoly","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0011","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.bbmt.2018.05.018","article-title":"A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from fondazione Italiana Linfomi","volume":"24","author":"Olivieri","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0012","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2022-169096","article-title":"Hematopoietic stem cell transplantation activity for lymphoma: a multicentric study by the transplantation and cellular therapy Mexican working group","volume":"140","author":"Colunga-Pedraza","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0013","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41409-020-01071-2","article-title":"Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma\u2014a retrospective study from the BSBMT (BEAM versus LEAM)","volume":"56","author":"Kelsey","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/09636897231179364","article-title":"BeEAM (Bendamustine, etoposide, cytarabine, melphalan) versus BEAM (Carmustine, etoposide, cytarabine, melphalan) as conditioning regimen before autologous haematopoietic cell transplantation: a systematic review and meta-analysis","volume":"32","author":"Wu","year":"2023","journal-title":"Cell Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.12659\/AOT.918259","article-title":"BEAM-modified conditioning therapy with Cisplatin+Dexamethasone instead of Carmustine prior to autologous hematopoietic stem cell transplantation (HSCT) in patients with hodgkin and non-Hodgkin lymphoma","volume":"24","author":"Ron-Maga\u00f1a","year":"2019","journal-title":"Ann Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0016","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/bmt.2016.3","article-title":"Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers","volume":"51","author":"Arai","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0017","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41420-021-00554-5","article-title":"Platinum drugs and taxanes: can we overcome resistance?","volume":"7","author":"Sazonova","year":"2021","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0018","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000040969","article-title":"Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patients","volume":"102","author":"del Giglio","year":"1999","journal-title":"Acta Haematol"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0019","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.3390\/cancers12123841","article-title":"Melphalan, Etoposide, And Carboplatin Megatherapy With Autologous Stem Cell Transplantation In Children With Relapsing Or Therapy-Resistant Extracranial Germ-Cell Tumors\u2014A Retrospective Analysis","volume":"12","author":"Ussowicz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jval.2013.11.007","article-title":"Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer","volume":"17","author":"Lairson","year":"2014","journal-title":"Value in Health"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-022-01284-6","article-title":"Worked to the bone: antibody-based conditioning as the future of transplant biology","volume":"15","author":"Griffin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0022","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.32752","article-title":"Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation","volume":"126","author":"Jagadeesh","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.7112","article-title":"Autologous hematopoietic stem cell transplantation with a rituximab-containing preparative regimen for non-Hodgkin lymphoma","volume":"25","author":"Kamble","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0024","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0025","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0026","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2015.330","article-title":"Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation","volume":"51","author":"Tanaka","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0027","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.transproceed.2022.12.001","article-title":"Comparative efficacy and safety of beam and team conditioning regimens for autologous stem cell transplantation in lymphoma patients","volume":"55","author":"Deveci","year":"2023","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.00892","volume":"9","author":"Colita","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0029","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428190500527769","article-title":"Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation","volume":"47","author":"Puig","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0030","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1038\/s41598-021-93516-x","article-title":"BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy","volume":"11","author":"Hahn","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0031","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3109\/10428194.2015.1028054","volume":"56","author":"Sakellari","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0032","first-page":"350","article-title":"Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning","author":"Gherman","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0033","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/bmt.2016.35","article-title":"Haematopoietic cell transplants in Latin America","volume":"51","author":"Gale","year":"2016","journal-title":"Bone Marrow Transplant"},{"unstructured":"Instituto Mexicano del Seguro Social (IMSS), (2020, Jan). \"Portal de Compras del IMSS\" http:\/\/compras.imss.gob.mx; Accessed 20 Jan 2024.","key":"10.1016\/j.transproceed.2024.05.034_bib0034"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0035","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0036","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0037","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0038","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.bbmt.2019.02.022","article-title":"Allogeneic transplantation after myeloablative rituximab\/BEAM \u00b1 bortezomib for patients with relapsed\/refractory lymphoid malignancies: 5-year follow-up results","volume":"25","author":"Chamoun","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0039","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1365-2141.2009.07674.x","article-title":"Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation","volume":"145","author":"Ratanatharathorn","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transproceed.2024.05.034_bib0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13045-017-0487-y","article-title":"Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma","volume":"10","author":"Epperla","year":"2017","journal-title":"J Hematol Oncol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134524003580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134524003580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T05:16:04Z","timestamp":1724822164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134524003580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0041134524003580"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2024.05.034","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cisplatin as a Viable and Secure Alternative to Carmustine in BEAM-Based Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2024.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}